CHICAGO (EGMN) - The investigational compound BIBW 2992 is the first tyrosine kinase inhibitor that appears to be at least as effective as cetuximab in metastatic or recurrent head and neck cancer. In addition, the response rate for BIBW 2992 is twice that of the best results reported with other tyrosine kinase inhibitors (TKIs), according to Dr. Tanguy Seiwert who presented preliminary findings of an ongoing phase II trial at the annual meeting of the American Society of Clinical Oncology.BIBW 2992...